Siga Antiviral Studied by NIH Researchers as Monkeypox Treatment

Monkeypox patients and their clinicians in the US now have more options to access treatments as the NIH opened up a late-stage clinical trial Friday to evaluate Siga Technologies Inc.’s antiviral Tpoxx.

Doctors already are using Tpoxx to treat monkeypox. The US has shipped 37,000 treatment courses of the antiviral as of Sept. 2 from the Strategic National Stockpile. But there isn’t any data to establish the safety and effectiveness of using Tpoxx to treat monkeypox in humans; the Food and Drug Administration approved TPOXX in 2018 for smallpox, a close cousin of monkeypox, based on animal data. ...